Neural self-regulation pathways (None established; not a standard molecular target with an abbreviation.)

"Neural self-regulation pathways" refer collectively to **interconnected brain regions and neural circuits that enable individuals to regulate their emotions, thoughts, behaviors, and physiological responses toward achieving adaptive goals**, especially under stress or challenge. These include but are not limited to fronto-striatal connections between the **ventromedial prefrontal cortex (vmPFC)** and **nucleus accumbens (NAc)**—which play key roles in evaluative/motivational aspects of pain—and broader networks involving limbic structures like the amygdala for emotional regulation[1][6]. Self-regulatory capacity develops through both maturation of these neural systems during childhood/adolescence and through experience-dependent plasticity throughout life[3][5]. Dysfunction within these regulatory networks has been implicated across multiple psychiatric disorders including depression, anxiety disorders, chronic pain syndromes, OCD,[6] ADHD,[5] among others. While no single molecule defines this system—making it unsuitable as a canonical drug target—the concept guides research into therapies aimed at enhancing adaptive regulation via pharmacologic agents targeting constituent neurotransmitter systems or via behavioral interventions such as cognitive-behavioral therapy.[1][2][3]

Other names

Self-regulatory neural circuitsNeural pathways of self-controlBrain systems for cognitive/emotional regulation

Not applicable for the pathway itself; mechanisms depend on which neurotransmitter system or node within the network is targeted by drugs: - Modulating serotonergic/dopaminergic transmission in fronto-striatal circuits. - Enhancing neuroplasticity via BDNF-TrkB signaling for recovery/adaptation. - Altering activity in prefrontal cortex–nucleus accumbens–amygdala networks.